MX9709446A - Metodo para preparar un anticuerpo monoclonal, anticuerpo monoclonal, una composicion farmaceutica y un reactivo de diagnostico. - Google Patents

Metodo para preparar un anticuerpo monoclonal, anticuerpo monoclonal, una composicion farmaceutica y un reactivo de diagnostico.

Info

Publication number
MX9709446A
MX9709446A MX9709446A MX9709446A MX9709446A MX 9709446 A MX9709446 A MX 9709446A MX 9709446 A MX9709446 A MX 9709446A MX 9709446 A MX9709446 A MX 9709446A MX 9709446 A MX9709446 A MX 9709446A
Authority
MX
Mexico
Prior art keywords
antibody
monoclon
diagnostic
reactive
preparing
Prior art date
Application number
MX9709446A
Other languages
English (en)
Other versions
MXPA97009446A (es
Inventor
Petrus Gerardus A Steenbakkers
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of MX9709446A publication Critical patent/MX9709446A/es
Publication of MXPA97009446A publication Critical patent/MXPA97009446A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invencion se refiere a un método eficiente para producir anticuerpos monoclonales contra antígenos de superficie de células y virus. El método se adapta para antígenos, que están presentes solo en cantidades relativamente pequeñas, o antígenos de los cuales solo cantidades muy pequeñas están disponibles o antígenos que fácilmente pierden su conformacion in vivo. Así, el método de acuerdo a esta invencion comprende una serie de pasos, comprendiendo un paso en el cual las células B de un mamífero inyectado con material que comprende antígeno de superficie son enriquecidas con respecto al numero relativo de células B específicas, y un paso que comprende una técnica de fusion a pequeña escala.
MXPA/A/1997/009446A 1996-12-06 1997-12-03 Metodo para preparar un anticuerpo monoclonal, anticuerpo monoclonal, una composicion farmaceutica y un reactivo de diagnostico MXPA97009446A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP96203465 1996-12-06
EP96203465.8 1996-12-06
EP97201972.3 1997-06-27
EP97201972 1997-06-27

Publications (2)

Publication Number Publication Date
MX9709446A true MX9709446A (es) 1998-07-31
MXPA97009446A MXPA97009446A (es) 1998-11-09

Family

ID=

Also Published As

Publication number Publication date
AU4690897A (en) 1998-06-11
PL323572A1 (en) 1998-06-08
KR100543053B1 (ko) 2006-06-13
CA2221682C (en) 2011-10-18
US6392020B1 (en) 2002-05-21
AU733165B2 (en) 2001-05-10
BR9706236A (pt) 1999-05-04
ATE322507T1 (de) 2006-04-15
NO327047B1 (no) 2009-04-14
HU9702359D0 (en) 1998-03-02
NO975714D0 (no) 1997-12-05
KR19980063909A (ko) 1998-10-07
IL122233A (en) 2001-04-30
EP0856520A1 (en) 1998-08-05
DK0856520T3 (da) 2006-07-31
HUP9702359A3 (en) 2001-11-28
HUP9702359A2 (hu) 1998-09-28
PT856520E (pt) 2006-08-31
DE69735621T2 (de) 2006-08-24
PL193821B1 (pl) 2007-03-30
IL122233A0 (en) 1998-04-05
NZ329314A (en) 1999-02-25
JPH10179160A (ja) 1998-07-07
ES2262170T3 (es) 2006-11-16
DE69735621D1 (de) 2006-05-18
CA2221682A1 (en) 1998-06-06
US6020170A (en) 2000-02-01
US20020143150A1 (en) 2002-10-03
NO975714L (no) 1998-06-08
EP0856520B1 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
HU9702359D0 (en) Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent
HK1017270A1 (en) Method of ex vivo immunizing using heterologous intact bispecific and/or trispecific antibodies
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
CA2290485A1 (en) Method for the production of non-immunogenic proteins
CA2163989A1 (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0699755A3 (en) Process for obtaining modified immunoglobulins with reduced immunogenicity of the variable domains of a murine antibody, compositions containing them
AU2097692A (en) Method for the production of monoclonal antibodies utilizing a germfree animal
CA2286879A1 (en) Novel method for the production of anti-human antigen receptors and uses thereof
IL162430A0 (en) Soluble proteins comprising sequences from ctla4 receptor reactive with b7 antigen
IL97653A0 (en) Catalytic antibody components
PL330794A1 (en) Polypeptides capable of forming structures bonding an antigen exhibiting antigenic specificity in respect to antigenes rh d, dna sequences coding such polypeptides and method of producing and using them
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
EP0400464A1 (en) Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
WO2002012535B1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy
IL93234A (en) Methods for producing antibodies, antibody probes produced thereby, method for preparing and using antigens utilizing said probes and vaccines prepared therewith
AU4872790A (en) Rat monoclonal antibodies directed against human antigens and processes for preparation thereof
DE3783002D1 (de) Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega.
DE69332637D1 (de) Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
EP0889054A3 (de) Antikörper 67D2 gegen CD164
PT93394A (pt) Processo para a preparacao de celulas de hibridonas produzindo anticorpos ligaveis a moleculas de adesao intercelular
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: N.V. ORGANON.*

MM Annulment or lapse due to non-payment of fees